- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Trofuse-019: A Phase 3 Study of Adjuvant Pembrolizumab with or without Sac-TMTfor Resectable Stage II-IIIB (N2) NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1370; P3 Secondary endpoints include OS, distant metastasis-free survival (time from randomization to first documented distant metastasis by investigator review or death), disease-free survival by investigator review, lung cancer-specific survival (time from randomization to death due to lung cancer), safety, and patient-reported outcomes. Enrollment into this study will begin in April 2024.
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date, Metastases: KL264-01: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (clinicaltrials.gov) - Jun 21, 2024 P1/2, N=1300, Recruiting, Trial completion date: Apr 2026 --> Aug 2026 N=430 --> 1300 | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Aug 2025
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov) - Dec 14, 2023 P2, N=110, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Aug 2023 --> Aug 2024
|